Internal medicine, Oncology, Lung cancer, Cancer and Surgery are his primary areas of study. His study in Clinical trial, Performance status, Randomized controlled trial, Regimen and Clinical endpoint is done as part of Internal medicine. David R. Gandara interconnects Phases of clinical research, Epidermal growth factor receptor, Pathology, Docetaxel and Radiation therapy in the investigation of issues within Oncology.
His Lung cancer research is multidisciplinary, relying on both Respiratory disease, Chemotherapy, Carboplatin, Carcinoma and Hazard ratio. His biological study spans a wide range of topics, including Ondansetron and Anesthesia. His work in Surgery tackles topics such as Placebo which are related to areas like Gastroenterology.
David R. Gandara spends much of his time researching Internal medicine, Oncology, Lung cancer, Chemotherapy and Cancer. His studies in Internal medicine integrate themes in fields like Gastroenterology and Surgery. His work carried out in the field of Oncology brings together such families of science as Carboplatin and Carcinoma.
In his study, Pathology is inextricably linked to Cancer research, which falls within the broad field of Lung cancer. His research integrates issues of Regimen, Radiation therapy and Toxicity in his study of Chemotherapy. His research links Pharmacology with Cancer.
His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Cancer research and Atezolizumab. His work in Docetaxel, Phases of clinical research, Chemotherapy, Clinical endpoint and Clinical trial is related to Internal medicine. His Oncology research integrates issues from Biomarker, Cancer, Immunotherapy and Lung.
His Lung cancer study combines topics in areas such as Targeted therapy, Carcinoma, Epidermal growth factor receptor and Hazard ratio. His Cancer research study also includes fields such as
The scientist’s investigation covers issues in Internal medicine, Oncology, Lung cancer, Atezolizumab and Cancer research. His research combines Surgery and Internal medicine. The Oncology study combines topics in areas such as Carboplatin, Clinical endpoint, Phases of clinical research and Confidence interval.
His Lung cancer study incorporates themes from Targeted therapy, Carcinoma, Intensive care medicine and Hazard ratio. His Atezolizumab research incorporates themes from PD-L1, Randomized controlled trial and Cancer immunotherapy. David R. Gandara has included themes like Cancer, Somatic evolution in cancer, Mutation, Cyclin-dependent kinase and Exon in his Cancer research study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio Vittorio Scagliotti;Purvish Parikh;Joachim von Pawel;Bonne Biesma.
Journal of Clinical Oncology (2008)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park.
The Lancet (2017)
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton;Robert Livingston;David H Johnson;James Rigas.
The New England Journal of Medicine (2005)
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
Karen Kelly;John Crowley;Paul A. Bunn;Cary A. Presant.
Journal of Clinical Oncology (2001)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe.
Lancet Oncology (2015)
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S Albain;R Suzanne Swann;Valerie W Rusch;Andrew T Turrisi.
The Lancet (2009)
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
Kathy S. Albain;Valerie W. Rusch;John J. Crowley;Thomas W. Rice.
Journal of Clinical Oncology (1995)
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Reginald V N Lord;Jan Brabender;David R Gandara;Vicente Alberola.
Clinical Cancer Research (2002)
Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study
Fred R. Hirsch;Marileila Varella-Garcia;Jason McCoy;Howard West.
Journal of Clinical Oncology (2005)
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
Antoinette J. Wozniak;John J. Crowley;Stanley P. Balcerzak;Geoffrey R. Weiss.
Journal of Clinical Oncology (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: